Anika Therapeutics Inc
Company Profile
Business description
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Contact
32 Wiggins Avenue
BedfordMA01730
USAT: +1 781 457-9000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
235
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
stocks
Morningstar's verdict on SpaceX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 10.70 | 0.12% |
| CAC 40 | 8,355.07 | 14.36 | 0.17% |
| DAX 40 | 24,713.87 | 179.71 | -0.72% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,429.41 | 0.56 | 0.01% |
| HKSE | 23,412.18 | 75.90 | 0.33% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 69,174.97 | 613.41 | -0.88% |
| NZX 50 Index | 13,400.66 | 35.11 | -0.26% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,808.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,110.81 | 4.56 | 0.11% |